An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB. 1.5 and other mutants
Z Liu, J Li, S Pei, Y Lu, C Li, J Zhu, R Chen… - Frontiers in Cellular …, 2023 - frontiersin.org
The rapid evolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
has led to the emergence of new variants with different genetic profiles, with important …
has led to the emergence of new variants with different genetic profiles, with important …
Saline nasal irrigation and gargling in COVID-19: a multidisciplinary review of effects on viral load, mucosal dynamics, and patient outcomes
With unrelenting SARS-CoV-2 variants, additional COVID-19 mitigation strategies are
needed. Oral and nasal saline irrigation (SI) is a traditional approach for respiratory …
needed. Oral and nasal saline irrigation (SI) is a traditional approach for respiratory …
The coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with nirmatrelvir …
Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally …
AK Padhi, T Tripathi - Biochemical and Biophysical Research …, 2022 - Elsevier
Shortly after the onset of the COVID-19 pandemic, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has acquired numerous variations in its intracellular proteins to …
coronavirus 2 (SARS-CoV-2) has acquired numerous variations in its intracellular proteins to …
Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses
V Fumagalli, P Di Lucia, M Ravà, D Marotta… - EMBO molecular …, 2023 - embopress.org
Alongside vaccines, antiviral drugs are becoming an integral part of our response to the
SARS‐CoV‐2 pandemic. Nirmatrelvir—an orally available inhibitor of the 3‐chymotrypsin …
SARS‐CoV‐2 pandemic. Nirmatrelvir—an orally available inhibitor of the 3‐chymotrypsin …
Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment
CC Lai, PR Hsueh - Journal of Medical Virology, 2023 - Wiley Online Library
Abstract Nirmatrelvir/ritonavir (NMV‐r) is an effective anti‐SARS‐CoV‐2 agent and has been
recommended in the treatment of nonhospitalized patients with COVID‐19. In rare …
recommended in the treatment of nonhospitalized patients with COVID‐19. In rare …
Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: systematic review and meta …
KM Souza, G Carrasco, R Rojas-Cortés… - Plos one, 2023 - journals.plos.org
Objective To assess the effectiveness of nirmatrelvir-ritonavir in the treatment of outpatients
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …
Real-world effectiveness of nirmatrelvir/ritonavir on coronavirus disease 2019–associated hospitalization prevention: a population-based cohort study in the province …
JL Kaboré, B Laffont, M Diop, MR Tardif… - Clinical Infectious …, 2023 - academic.oup.com
Background Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death
before Omicron, but updated real-world evidence studies are needed. This study aimed to …
before Omicron, but updated real-world evidence studies are needed. This study aimed to …
Clinical efficacy of Jingyin granules, a Chinese patent medicine, in treating patients infected with coronavirus disease 2019
B Chen, X Yu, L Zhang, W Huang, H Lyu, Y Xu, J Shen… - Phytomedicine, 2023 - Elsevier
Background Jingyin granules (JY), one patented Chinese herbal formula, have been
advised for treating coronavirus disease 2019 (COVID-19) in China. As of now, the safety …
advised for treating coronavirus disease 2019 (COVID-19) in China. As of now, the safety …